10 Peregrine Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $PPHM | NASDAQ:PPHM | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s)Consensus Rating:Hold (Score: 2.00)Consensus Price Target: $5.40 (125.00% upside) Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare1/17/2014JPMorgan Chase & Co.Lower Price Target$12.00 -> $9.50View 8/1/2013ZacksDowngradeOutperform -> Neutral$1.70View 7/3/2013ZacksUpgradeNeutral -> Outperform$1.60View 6/28/2013Roth CapitalLower Price Target$7.00 -> $5.00View 6/3/2013Roth CapitalBoost Price TargetBuy$4.00 -> $7.00View 3/5/2013Piper JaffrayInitiated CoverageOverweight$2.50View 1/7/2013Roth CapitalUpgradeNeutral -> Buy$2.70View 9/27/2012MLV & Co.Initiated CoverageBuy$4.50 -> $2.00View 9/24/2012Roth CapitalDowngradeBuy -> Neutral$9.00 -> $0.70View 9/10/2012Roth CapitalBoost Price Target$5.00 -> $9.00View 9/7/2012Roth CapitalReiterated RatingBuy$5.00View 8/15/2012Roth CapitalReiterated RatingBuy$5.00View (Data available from 3/9/2012 forward) Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare3/7/2014Q314($0.06)($0.06)$5.09 million$3.90 millionViewN/AView 12/10/2013Q2($0.05)($0.05)$5.74 million$7.35 millionViewListenView 9/9/2013Q1 2014($0.05)($0.05)$4.75 million$4.69 millionViewN/AView 7/11/2013Q4 2013($0.06)($0.06)$3.57 million$4.25 millionViewN/AView 3/12/2013Q3 2013($0.07)($0.04)$3.90 million$7.04 millionViewN/AView 12/10/2012-0.08($0.09)($0.08)$4.03 million$4.03 millionViewN/AView 9/10/2012Q113($0.11)($0.07)$3.97 million$4.25 millionViewN/AView 7/16/2012($0.13)($0.10)ViewN/AView 3/9/2012($0.13)($0.13)ViewN/AView 12/12/2011($0.13)($0.16)ViewN/AView 9/9/2011($0.14)($0.11)ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)No insider trades for this company have been tracked by Analyst Ratings Network About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of cancer and viral infections. The Company is advancing its two Phase II oncology platforms, as well as its Phase I hepatitis C virus (HCV) program. The Companyâ€™s Phase II trials in lung, breast, and brain cancers have demonstrated results, leading to two randomized Phase II trials in non-small cell lung cancer (NSCLC). Its pipeline of investigational monoclonal antibodies includes bavituximab and cotara. Bavituximab is a phosphatidylserine (PS) targeting monoclonal antibody, which represents an approach to treating cancer and has demonstrated broad-spectrum potential in multiple solid tumors. Its brain cancer therapy, Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue. Headlines: (3/7) Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments (3/4) Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at ... (2/27) Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering (2/27) Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 (2/19) Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering (2/19) Peregrine Pharmaceuticals Announces Upcoming Events (3/7) Earnings Reaction History: Peregrine Pharmaceuticals Corporation, 57.1% Follow-Through Indicator, 14.5% Sensitive (2/11) Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: PPHM CUSIP: Key Metrics: Previous Close: $2.6150 Day Moving Average: $1.84200 Day Moving Average: $1.4973 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $384.8MCurrent Quarter EPS Consensus Estimate: $-0.23 EPS Additional Links: View PPHM on Google FinanceView PPHM on Yahoo FinanceView PPHM's Company Profile on ReutersSearch for Peregrine Pharmaceuticals on Google Peregrine Pharmaceuticals (NASDAQ:PPHM) Chart for Sunday, March, 9, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.